PPD Shortage Prompts CDC to Issue New Recommendations for TB Testing

Date: 09/26/19

The Centers for Disease Control (CDC) has announced that they are experiencing a three to ten month nationwide shortage of Aplisol, a product of Par Pharmaceuticals, and one of two purified-protein derivative (PPD) tuberculin antigens licensed by the Food and Drug Administration (FDA) for use in performing tuberculin skin tests.

Providers who currently use Aplisol will need to consider alternate options covered by Medicaid.  Please refer to the article below for guidance:  

• PPD Shortage Prompts CDC to Issue New Recommendations for TB Testing